Ավստրալիա - անգլերեն - APVMA (Australian Pesticides and Veterinary Medicines Authority)

pooma fertilizers pty ltd - glyphosate present as the isopropylamine salt - aqueous concentrate - glyphosate present as the isopropylamine salt glycine active 360.0 g/l - herbicide - agricultural area - general | almond over 3 years old | avocado, over 3 years old | banana, over 3 years old | buildings - aroun - african boxthorn | african lovegrass | amaranth or amaranthus | amsinckia,yellow burrweed or burr grass | annual or wimmera ryegrass | annual phalaris | annual weeds | apple box | argyle apple | artichoke thistle | barley grass | barnyard grass or water grass | barnyard or water grass | bent grass - agrostis spp. | bitou bush or boneseed | black bindweed | blackberry | bladder ketmia | blady grass | bracken | brome grass | brown beetle or silver top grass | bullich | burr medic | californian thistle | caltrop or yellow vine | camel or afghan melon | canary grass | canary grasses | capeweed | carpet grass | cat's ear or flatweed | chickweed | cobbler's pegs | cocksfoot | columbus grass - seedling | common fumitory | common reed or phragmites | couch grass | crofton weed | cudweed | cumbungi | deadnettle | dock - seedling | english couch or rope twitch | flooded gum | fumitory | furze or gorse | ghost gum | glyceria or reed sweet grass | ground or annual ground cherry | groundsel bush | guinea grass | gum toppe

Ավստրալիա - անգլերեն - APVMA (Australian Pesticides and Veterinary Medicines Authority)

sanonda (australia) pty ltd - glyphosate present as the isopropylamine salt - aqueous concentrate - glyphosate present as the isopropylamine salt glycine active 360.0 g/l - herbicide - agricultural area - general | agricultural/farm buildings | avocado, over 3 years old | banana, over 3 years old | citrus over 3 - african boxthorn | african lovegrass | amaranth or amaranthus | annual or wimmera ryegrass | artichoke thistle | bamboo | barley grass | barnyard or water grass | bathurst burr | bent grass - agrostis spp. | bitou bush or boneseed | blackberry | blady grass | bracken | brome grass | brown beetle or silver top grass | bullich | californian thistle | caltrop or yellow vine | camphor laurel | canary grass | capeweed | carpet grass | cat's ear or flatweed | cereal - self-sown | chickweed | chinese scrub | cobbler's pegs | cocksfoot | common reed or phragmites | couch grass | crofton weed | cumbungi | deadnettle | english couch or rope twitch | eucalyptus | flooded gum | fumitory | furze or gorse | ghost gum | glyceria or reed sweet grass | ground or annual ground cherry | groundsel bush | guinea grass | gum topped bloodwood | hawthorn | hedge or wild mustard | hoary cress or whiteweed | jarrah | johnson grass | kangaroo grass | kikuyu grass | lantana - lantana camara | lesser swinecress or bittercress | liverseed

Ավստրալիա - անգլերեն - APVMA (Australian Pesticides and Veterinary Medicines Authority)

axichem pty ltd - cypermethrin; triadimenol - suspension concentrates for seed treatment (fs) - cypermethrin pyrethroid active 4.0 g/l; triadimenol triazole active 150.0 g/l - mixed function seed treat

Նոր Զելանդիա - անգլերեն - Ministry for Primary Industries

elanco australasia pty ltd - silicon oestradiol suspension (20%) - silicon oestradiol suspension (20%) 366.1 g/kg - hormonal growth promotant

Նոր Զելանդիա - անգլերեն - Ministry for Primary Industries

elanco australasia pty ltd - chlorhexidine digluconate (free base); spinosad - chlorhexidine digluconate (free base) 0.56 g/kg; spinosad 2.8 g/kg - ectoparasiticide

Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

leo pharma pty ltd - calcipotriol, quantity: 20.5 microgram/g; betamethasone dipropionate, quantity: 264 microgram/g (equivalent: betamethasone, qty 205 microgram/g) - foam - excipient ingredients: polyoxypropylene-11 stearyl ether; liquid paraffin; dl-alpha-tocopherol; white soft paraffin; butane; methyl ether - enstilar is indicated for the topical treatment of psoriasis vulgaris in adults.

Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

bristol-myers squibb australia pty ltd - abatacept, quantity: 125.875 mg - injection - excipient ingredients: sucrose; water for injections; monobasic sodium phosphate; poloxamer; nitrogen; dibasic sodium phosphate - orencia in combination with methotrexate is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have had an insufficient response or intolerance to other disease modifying anti-rheumatic drugs (dmards), such as methotrexate or tumour necrosis factor (tnf) blocking agents. a reduction in the progression of joint damage and improvement in physical function have been demonstrated during combination treatment with orencia and methotrexate.,orencia in combination with methotrexate is also indicated in the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate.,orencia is indicated for reducing signs and symptoms in paediatric patients 6 years of age and older with moderately to severely active polyarticular juvenile idiopathic arthritis who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (dmards). orencia may be used as monotherapy or concomitantly with methotrexate (mtx). (there is no clinical trial data for the use of orencia subcutaneous formulation in children, therefore its use in children cannot be recommended.),orencia is indicated for the treatment of active psoriatic arthritis (psa) in adults when the response to previous disease-modifying anti-rheumatic drug (dmard) therapy has been inadequate. orencia can be used with or without non-biologic dmards.,orencia should not be administered concurrently with other biological dmards (eg, tnf inhibitors, rituximab, or anakinra).

Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

medtronic australasia pty ltd - 35852 - defibrillator, implantable, automatic - the medtronic model dvmc3d4 evera mri s vr surescan single chamber, implantable cardioverter defibrillator (icd) is a multiprogrammable cardiac device that monitors and regulates the patient?s heart rate by providing single chamber, rate-responsive bradycardia pacing and ventricular tachyarrhythmia therapies. the evera mri s vr surescan system is intended to provide ventricular antitachycardia pacing and ventricular defibrillation for automated treatment of life-threatening ventricular tachyarrhythmias.

Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

astellas pharma australia pty ltd - enzalutamide, quantity: 40 mg - capsule, soft - excipient ingredients: gelatin; purified water; caprylocaproyl macrogolglycerides; butylated hydroxyanisole; butylated hydroxytoluene; titanium dioxide; sorbitol; glycerol; propylene glycol; ethyl acetate; ethanol; isopropyl alcohol; strong ammonia solution; iron oxide black; macrogol 400; polyvinyl acetate phthalate - xtandi is indicated for:,? the treatment of patients with metastatic hormone-sensitive prostate cancer.,? the treatment of patients with non-metastatic castration-resistant prostate cancer (see prosper, section 5.1 clinical trials).,? the treatment of patients with metastatic castration resistant prostate cancer following failure of androgen deprivation therapy in whom chemotherapy is not yet indicated.,? the treatment of patients with metastatic castration-resistant prostate cancer who have previously received docetaxel.

Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

bristol-myers squibb australia pty ltd - abatacept, quantity: 125.875 mg - injection - excipient ingredients: dibasic sodium phosphate; nitrogen; water for injections; sucrose; poloxamer; monobasic sodium phosphate - orencia in combination with methotrexate is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have had an insufficient response or intolerance to other disease modifying anti-rheumatic drugs (dmards), such as methotrexate or tumour necrosis factor (tnf) blocking agents. a reduction in the progression of joint damage and improvement in physical function have been demonstrated during combination treatment with orencia and methotrexate.,orencia in combination with methotrexate is also indicated in the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate.,orencia is indicated for reducing signs and symptoms in paediatric patients 6 years of age and older with moderately to severely active polyarticular juvenile idiopathic arthritis who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (dmards). orencia may be used as monotherapy or concomitantly with methotrexate (mtx). (there is no clinical trial data for the use of orencia subcutaneous formulation in children, therefore its use in children cannot be recommended.),orencia is indicated for the treatment of active psoriatic arthritis (psa) in adults when the response to previous disease-modifying anti-rheumatic drug (dmard) therapy has been inadequate. orencia can be used with or without non-biologic dmards.,orencia should not be administered concurrently with other biological dmards (eg, tnf inhibitors, rituximab, or anakinra).